Vera Therapeutics Gains FDA Accelerated Approval for Trutakna in IgA Nephropathy

Vera Therapeutics' Trutakna (atacicept-vymj) now carries an FDA accelerated approval for reducing proteinuria in adults with primary IgA nephropathy at risk of disease progression, an approval pathway that places immediate obligations on the manufacturer's post-marketing commitments and confirmatory trial infrastructure.

The approval rests on a surrogate endpoint: a 46% average reduction in urine protein-to-creatinine ratio at nine months versus placebo, measured across the first 203 patients in a randomized, double-blind, placebo-controlled trial (NCT04716231) in adults with biopsy-confirmed disease. Proteinuria reduction is accepted as reasonably likely to predict clinical benefit, but the FDA has not established that Trutakna slows long-term kidney function decline. Continued approval is contingent on verification of that clinical benefit through the ongoing confirmatory trial.

For regulatory affairs leads managing post-approval commitments, the accelerated approval condition is the operative constraint. The confirmatory trial must be completed, and failure to demonstrate a durable effect on kidney function decline would place the approval at risk. Biologics teams should map the trial's completion timeline against their lifecycle management plans accordingly.

Trutakna is the first approved agent to target both B cell activating factor (BAFF) and A Proliferation Inducing Ligand (APRIL), proteins involved in the survival and maturation of immune cells responsible for producing the aberrant IgA antibody driving nephropathy. It is administered subcutaneously once weekly, a delivery format that carries its own labeling and device-validation considerations under 21 CFR Part 211 for manufacturers supplying prefilled or auto-injector formats.

On the safety side, Trutakna's immunosuppressive mechanism introduces infection-risk monitoring requirements. Patients must be assessed for active infections prior to initiation, and live vaccines are contraindicated within 30 days before starting treatment or during the treatment period, a patient-management protocol that QA and pharmacovigilance teams will need to reflect in their risk management documentation.

The product also received Priority Review and Breakthrough Therapy designation, designations that compress FDA review timelines but do not alter the post-approval evidentiary standard the confirmatory trial must meet.

The confirmatory trial's readout on long-term kidney function decline will determine whether Trutakna's market position converts from conditional to fully verified clinical benefit.

Source: U.S. Food and Drug Administration, What's New: Drugs RSS Feed, 7 July 2026.